Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | CheckMate 650: nivolumab + ipilimumab, ipilimumab alone, or cabazitaxel in mCRPC

Russell Kent Pachynski, MD, Washington University School of Medicine, St. Louis, MO, shares additional results of the Phase II CheckMate 650 (NCT02985957) trial evaluating nivolumab plus ipilimumab, ipilimumab alone, or cabazitaxel in men with metastatic castration-resistant prostate cancer. Coprimary endpoints were objective response rate (ORR) and radiographic progress-free survival (PFS). Safety is a secondary endpoint and exploratory endpoints include correlation of biomarkers with efficacy. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.